This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
mCRPC in focus

Transcript: The continuing need for improved mCRPC treatments

Last updated:4th Sep 2024
Published:4th Sep 2024

Professor Karim Fizazi

All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.

Well, I guess, prostate cancer remains a very important disease. Many men will get it, probably one out of eight men or so in Western countries.

Fortunately enough, not so many men will die from it, but still it remains a big killer, probably a number two or three cancer killer in many Western countries. In France, my country for example, unfortunately, approximately 8,000 men die from the disease every year.

So this remains very significant, not even speaking about the morbidity many of the men suffer from. So I think it remains key to improve all the treatments for these men.

View the video

Welcome:

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information 

 

By providing your email address, you are opting in to receive our monthly newsletter.

We will never share your data, and you can withdraw consent at any time. Read our privacy policy here.